Lupin has received final USFDA approval to market generic Nadolol tablets, used for treatment of hypertension, in the American market. The drug will be marketed in 20 mg, 40 mg and 80 mg strengths. The product is a generic version of US WorldMeds LLC’s Corgard tablets in the same strengths. According to estimates, Nadolol tablets USP in the three strengths had annual sales of around USD 109.8 million in the US. The tablets are indicated for management of patients with angina pectoris and for the treatment of hypertension.
Company Profile : Lupin Ltd
Leave a Reply